Long-term efficacy of neonatal hepatitis B vaccination against chronic hepatitis B virus infection and chronic liver disease: a cross-sectional study based on Qidong Hepatitis B Intervention Study.
- VernacularTitle:启东乙型肝炎干预研究:2013年随访人群HBV感染及慢性肝病现患调查
- Author:
Taoyang CHEN
1
;
Chunfeng QU
2
;
Hongyu YAO
1
;
Lingling LU
1
;
Jian FAN
1
;
Yuting WANG
3
;
Fei HUANG
1
;
Jianhua LU
1
;
Zhengping NI
1
;
Chunsun FAN
1
;
Yawei ZHANG
4
;
Author Information
- Publication Type:Journal Article
- MeSH: Adult; China; Cross-Sectional Studies; Female; Hepatitis B Antibodies; blood; Hepatitis B Surface Antigens; blood; Hepatitis B Vaccines; therapeutic use; Hepatitis B virus; Hepatitis B, Chronic; prevention & control; Humans; Liver Cirrhosis; Male; Prevalence; Vaccination; statistics & numerical data
- From: Chinese Journal of Epidemiology 2016;37(1):64-67
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the long-term protection efficacy of neonatal hepatitis B vaccination on chronic hepatitis B (CHB) and liver fibrosis and cirrhosis in adults.
METHODSFrom January to October, 2013, a cross-sectional study was conducted among the participants from Qidong Hepatitis B Intervention Study (QHBIS), who were selected through stratified random sampling. The detections of serum alanine aminotransferase (ALT), HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe were conducted and ultrasonography on liver, gallbladder and spleen was performed for them. The positive rates of each serologic markers, the prevalence of active CHB and liver fibrosis and cirrhosis were calculated, the gender specific differences between vaccination group and control group were compared with Chi-square test.
RESULTSA total of 4 421 participants aged (25.59±1.84) years in vaccination group and 3 880 participants aged (26.61±2.24) years in control group were surveyed. The positive rates of HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were 2.38%, 37.73%, 3.78%, 0.57% and 2.15% in vaccination group, and 9.02%, 29.41%, 16.83%, 2.73% and 8.87% in control group, respectively, the differences between two groups were statistically significant (all P<0.05). The prevalence of active CHB and liver fibrosis and cirrhosis were 0.45% and 0.16% in vaccination group, 1.29% and 0.39% in control group, the differences between two groups were statistically significant (P<0.05). The active CHB prevalence was lower in females than in males in both vaccination group and control group (P<0.05). The liver fibrosis and cirrhosis prevalence was lower in females than in males in control group (P<0.05); whereas, no statistical significant difference in liver fibrosis & cirrhosis prevalence between males and females was found in vaccination group (P>0.05).
CONCLUSIONSProtection conferred by neonatal hepatitis B vaccination could last to marrying age. The gender specific difference in protection efficacy needs further study.